Articles

Eric Hsu, Account Director of Alliance Management at Samsung Biologics, examines how we can apply the lessons of the COVID-19 pandemic to the biopharma industry in future. He also explores the ongoing trends in biologics manufacturing and the increased...

Once the patent on a previously ground-breaking blockbuster molecule comes to an end, there is an opportunity for biosimilar versions of this product to enter the market. Often presenting a more cost-effective alternative, biosimilars can provide greater access to...

For companies in the early stages of developing a new parenteral therapy, the focus within the product teams is naturally on the molecule and the science behind it. But when it’s time to transition that molecule from lab to...

Viral vectors play a vital role in the development of cell and gene therapies (C&GTs). By delivering genetic material to patients’ cells to replace dysfunctional or damaged DNA, these complex tools have helped to change patient outlook dramatically, particularly...

The healthcare industry has undergone evident transformations in the past ten years. Innovations involving artificial intelligence (AI) driven technologies have uplifted diagnostics and aftercare, and have improved patient experience significantly. Furthermore, investments in health tech have had an overall...

With sustainability as a daily challenge and energy in short supply, a dependable management plan is essential If someone asks me today, “As an executive in the biopharma industry, what are the issues that keep you awake at night?” my...

Reacting rapidly after the initial onset of the pandemic the biopharma industry accelerated its research into advanced anti-viral modalities including messenger RNA (mRNA) vaccines. As the pharma industry’s leaders responded to the crisis, the pandemic revealed how critical outsourcing...